Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $8.24

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have earned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $8.37.

Several research analysts recently issued reports on the stock. Wedbush reissued a “neutral” rating and set a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers bought 21,000 shares of the business’s stock in a transaction dated Wednesday, April 30th. The stock was acquired at an average price of $1.40 per share, with a total value of $29,400.00. Following the completion of the purchase, the director now directly owns 281,192 shares of the company’s stock, valued at approximately $393,668.80. This trade represents a 8.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Voya Investment Management LLC grew its stake in Zentalis Pharmaceuticals by 14.1% during the 4th quarter. Voya Investment Management LLC now owns 57,017 shares of the company’s stock valued at $173,000 after acquiring an additional 7,058 shares in the last quarter. Wells Fargo & Company MN grew its stake in Zentalis Pharmaceuticals by 26.8% during the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company’s stock valued at $105,000 after acquiring an additional 7,305 shares in the last quarter. Cerity Partners LLC grew its stake in Zentalis Pharmaceuticals by 58.7% during the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock valued at $33,000 after acquiring an additional 7,579 shares in the last quarter. Corton Capital Inc. purchased a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at about $32,000. Finally, State of Wyoming grew its stake in Zentalis Pharmaceuticals by 30.1% during the 1st quarter. State of Wyoming now owns 45,176 shares of the company’s stock valued at $72,000 after acquiring an additional 10,460 shares in the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $1.30 on Tuesday. The firm has a fifty day moving average price of $1.34 and a 200 day moving average price of $1.95. Zentalis Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $5.44. The stock has a market cap of $93.54 million, a PE ratio of -0.42 and a beta of 1.61.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.42 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.